Adar Poonawalla, the CEO of Serum Institute of India, talked to NDTV in an exclusive interview and answered a bunch of questions on an anti-Covid vaccine candidate. He said the efficacy of the vaccine will only be fully known after one or two years of use. "The indicators are all positive, but we will need to wait a year or two to be certain that the vaccine candidate will in fact have a long-term effect," he said. | NDTV

How producing coronavirus vaccine has been different from other vaccines? Adar Poonawalla, CEO, Serum Institute of India, tells us. #Newstrack with Rahul Kanwal | India Today

54K views · 135 reactions | Majority of the first 50 million doses will go to India, said the chief of world's largest drugmaker by volume Adar Poonawalla amid delay in approval for the COVID-19 vaccine developed by Oxford and AstraZeneca. In addition, the dry run for COVID vaccination drive expected to cover 30 crore people in the first phase began today in four states: Andhra Pradesh, Assam, Gujarat and Punjab. | NDTV | Facebook

Adar Poonawalla, CEO of Serum Institute of India, says they hope to start producing a vaccine for COVID-19 by May end so that by the time trials by Oxford University get over in September, India could have a product to give to the country and the world. | NDTV

13K views · 86 reactions | Watch | Serum Institute CEO Adar Poonawalla spoke on PM Modi’s visit to #vaccine lab in Pune. He said that he was amazed by the Prime Minister’s knowledge about vaccines and vaccine production. | Hindustan Times | Facebook

How does the covishield vaccine is compared with other vaccines like Moderna and Pfizer. Serum Institute CEO Adar Poonawalla tells us in this #exclusive interview with Rahul Kanwal #ITVideo #CoronaVaccine #Covishield Full show: https://bit.ly/3555Jgm For real time updates on news that matters most, Like us on Facebook | India Today